Drug Interactions between Prepopik and taletrectinib

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration with antacids or other agents with acid neutralizing or reducing effects may decrease the gastrointestinal absorption and plasma concentrations of taletrectinib due to increased gastric pH. Taletrectinib displays pH-dependent aqueous solubility, with increased solubility at lower pH. The magnitude of interaction may be dose-dependent and related to the degree of acid suppression achieved.

MANAGEMENT: The possibility of a reduced or subtherapeutic response to taletrectinib should be considered during coadministration with antacids or other agents that can increase gastric pH. If an antacid is required, the antacid should be taken 2 hours before or 2 hours after administration of taletrectinib. The same precaution may be applicable to other drugs with antacid effects. Patients should be advised to contact their doctor if their symptoms worsen or their condition changes, as reduced drug absorption may lead to decreased therapeutic effectiveness.

Consumer information for this interaction is not currently available.

MONITOR: The use of bowel cleansing preparations may increase the risk of ventricular arrhythmia, particularly torsade de pointes, in patients treated with drugs that prolong the QT interval. Severe and potentially fatal cases of electrolyte disorders and arrhythmias have been reported in elderly patients using bowel cleansing products. Electrolyte disturbances including hypokalemia and hypomagnesemia are known risk factors for torsade de pointes associated with QT interval prolongation.

MANAGEMENT: Caution is advised when bowel cleansing preparations are prescribed in patients treated with drugs that prolong the QT interval. Monitoring of baseline and posttreatment serum electrolyte levels is recommended, particularly in the elderly. Patients should be instructed to drink plenty of clear liquids before, during, and after the bowel preparation process. Consideration should be given to consumption of 36 to 48 fluid ounces of a carbohydrate-electrolyte solution in the six hours before the first dose. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.